104317-95-5

Basic information

• Product Name: (4-CHLORO-3-IODOPHENYL)METHANOL
• Synonyms: (4-CHLORO-3-IODOPHENYL)METHANOL
• CAS NO: 104317-95-5
• Molecular Formula: C₇H₆ClIO
• Molecular Weight: 268.48
• Mol File: 104317-95-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-CHLORO-3-IODOPHENYL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLORO-3-IODOPHENYL)METHANOL(104317-95-5)
• EPA Substance Registry System: (4-CHLORO-3-IODOPHENYL)METHANOL(104317-95-5)

Safety Data

• Hazardous Substances Data: 104317-95-5(Hazardous Substances Data)

Usage

General Description

(4-Chloro-3-iodophenyl)methanol is a chemical compound with the molecular formula C7H6ClIO. It is an organic compound that contains both chlorine and iodine atoms, and it belongs to the class of phenylmethanols. (4-CHLORO-3-IODOPHENYL)METHANOL is used in the synthesis of various pharmaceuticals and organic compounds due to its unique chemical properties. It is also used as an intermediate in the production of agrochemicals and other fine chemical products. The chemical structure and properties of (4-Chloro-3-iodophenyl)methanol make it a versatile and valuable compound in the field of organic synthesis and chemical manufacturing.

Upstream product

• 42860-04-8 4-chloro-3-iodobenzoic acid 
• 74-11-3 para-chlorobenzoic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 276866-90-1 4-chloro-3-iodobenzaldehyde 

Downstream Products

• 136558-15-1 4-(bromomethyl)-1-chloro-2-iodobenzene 
• 276866-90-1 4-chloro-3-iodobenzaldehyde 

Relevant articles and documents

Discovery of G Protein-Biased Ligands against 5-HT7R

There has been significant attention concerning the biased agonism of G protein-coupled receptors (GPCRs), and it has resulted in various pharmacological benefits. 5-HT7R belongs to a GPCR, and it is a promising pharmaceutical target for the treatment of neurodevelopmental and neuropsychiatric disorders. Based on our previous research, we synthesized a series of 6-chloro-2′-methoxy biphenyl derivatives 1, 2, and 3 with a variety of amine scaffolds. These compounds were evaluated for their binding affinities to 5-HTR subtypes and their functional selectivity toward the Gs protein and the β-arrestin signaling pathways of 5-HT7R. Among them, 2-(6-chloro-2′-methoxy-[1,1′-biphenyl]-3-yl)-N-ethylethan-1-amine, 2b, was found to be a G-protein-biased ligand of 5-HT7R. In an in vivo study with Shank3 transgenic mice, the self-grooming behavior test was performed with 2b, which increased the duration of self-grooming. The experiments further suggested that 5-HT7R is associated with autism spectrum disorders (ASDs) and could be a therapeutic target for the treatment of stereotypy in ASDs.

2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar1, Q, and R1 to R5 are as described in the description, to their preparation, to

Indole derivatives as MCP-1 receptor antagonists

A compound of Formula I, wherein: R1 is hydrogen, halo, methyl, ethyl or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, trifluoromethyl, nitro, cyano, trifluoromethoxy, C(O)R7, or S(O)nR7 where n is 0, 1 or 2 and R7 is an alkyl group; R4 is a halo, trifluoromethyl, methylthio, methoxy, trifluoromethoxy or lower alkyl, lower alkenyl or lower alkynyl or COR8 where R8 is lower alkyl; R6 is hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl or COR9 where R9 is lower alkyl; provided that when R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy, R5 and R6 are both hydrogen, and one of R3 or R4 is not halo or trifluoromethyl; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonizing an MCP-1 mediated effect in a warm-blooded animal such as a human being.